Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 23, 2004 W.D. Crotty	Adolor Drug Comes Up Short The biotech company announces trial results that, once again, do not meet primary end points.
The Motley Fool September 5, 2006 Brian Lawler	Adolor: Positive Results, Negative Reaction The market seems confused by good results from Adolor's latest clinical trial. Investors willing to take a gamble on Adolor at this price may be in for huge rewards if the company and Glaxo can convince the FDA of Entereg's viability.
The Motley Fool September 14, 2007 Brian Lawler	FDA Keeps Adolor Waiting Adolor and partner GlaxoSmithKline continue playing the FDA waiting game, as the agency has still not decided whether to allow clinical trials of Adolor's top drug to continue.
The Motley Fool September 13, 2007 Brian Orelli	Progenics Progresses Progenics and partner Wyeth announce plans to start three new clinical trials on their constipation-relieving drug. The patient treatment time for the trials is relatively short, so investors won't have to wait too long to see how the drug performs.
The Motley Fool March 13, 2008 Brian Orelli	Progenics Down but Not Out Progenics Pharmaceuticals' drug to help patients after abdominal surgery fails in its phase 3 trial. Investors, take note.
The Motley Fool November 28, 2008 Brian Orelli	Will Patients Reject This Injection? Wyeth and Progenics release good trial data, but will patients want their constipation drug?
The Motley Fool August 29, 2007 Brian Lawler	Adolor Stays in the Ring Adolor takes another run at getting FDA approval for its lead drug. Shares of the biotech firm are up on news the FDA had accepted for review additional information about its ileus medication, Entereg.
The Motley Fool February 28, 2007 Brian Lawler	Time to Buy Shares of Adolor? Drug developer Adolor announces its fourth-quarter financial results as investors await pivotal clinical trial results.
The Motley Fool May 23, 2008 Brian Orelli	Progenics' Mixed Trial Data Progenics Pharmaceuticals and marketing partner Wyeth release both positive and negative clinical trial data.
The Motley Fool April 11, 2007 Brian Lawler	Adolor: Down and Out? The drug developer announces dour clinical trial results. Shares of Adolor crashed nearly 60% on the news.
The Motley Fool March 15, 2007 Brian Lawler	Adolor's New Plan Adolor updates investors on its plans for its lead drug program.
The Motley Fool January 14, 2004 W.D. Crotty	Adolor Pains Investors A punishing 32% one-day plunge reminds us that biotech is no picnic.
The Motley Fool July 10, 2007 Brian Lawler	Adolor Tries Again Adolor continues work on its second drug candidate. Investors will have to wait until early 2008 for some data to sink their teeth into.
The Motley Fool April 25, 2008 Brian Orelli	Progenics' Double Dose of Good News Its lead drug gets FDA approval and a positive EU recommendation.
The Motley Fool October 15, 2009 Brian Orelli	This Partnership Will Go No Further Wyeth and Progenics call it quits.
The Motley Fool January 13, 2004 David Nierengarten	Vicuron's Booster Shot With a new "super-tough" antibiotic, Vicuron's stock is super high.
The Motley Fool November 8, 2006 Brian Lawler	Stumbling Block for Adolor Another approvable letter from the FDA means investors may have to be patient.
The Motley Fool June 4, 2007 Brian Lawler	Progenics Is on the Clock The biotech's marketing application for its lead compound gets accepted for review. Investors, take note.
The Motley Fool June 12, 2007 Brian Lawler	Adolor Is Still Swinging The drugmaker bumps into the FDA as it pushes to do more testing of Entereg.
The Motley Fool March 30, 2005 David Nierengarten	Soothing Results, But Pain for Investors Pain Therapeutics delivers again but its stock barely budged. What gives?
The Motley Fool March 9, 2007 Brian Lawler	Progenics Gets Backed Up Progenics Pharmaceutics and drugmaker giant Wyeth announced a delay in one of their methylnaltrexone programs. Investors, take note.
The Motley Fool July 23, 2007 Brian Lawler	Progenics Gets Back In the Game Being the first approved to market an oral compound to treat one of the more painful side effects from opioid use will be a boon to whichever drugmaker can reach this goal. With the competitior Adolor looking more likely to be out of this race, Progenics is in the pole position once again.
The Motley Fool January 24, 2008 Brian Lawler	Adolor Advisory Panel Aftermath An FDA advisory panel votes favorably on Adolor's lead drug.
The Motley Fool May 1, 2007 Mike Havrilla	Heads Up, Biotech Investors Big news is in the offing for these companies. Pozen... Progenics... Zymogenetics... etc.
The Motley Fool May 12, 2004 Charly Travers	Cubist Addresses a Niche Market This small firm is developing antibiotics to meet a medical need.
The Motley Fool November 30, 2007 Brian Lawler	FDA Throws Adolor a Bone Pharmaceutical company Adolor gets an advisory panel hearing on its lead drug. Investors, take note.
The Motley Fool January 22, 2008 Brian Lawler	Adolor Under the FDA's Spotlight The FDA releases its documents on Adolor's lead drug, with surprising good news in advance of an advisory panel discussion. Investors, take note.
The Motley Fool March 4, 2010 Brian Orelli	A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan.
The Motley Fool June 16, 2005 Stephen D. Simpson	Farewell, Sweet Vicuron Pfizer purchased promising biotech Vicuron Pharmaceuticals for $29.10 as share in cash. Vicuron shareholders get a nice payday -- nearly 84% premium to its close and a 21% premium to its all-time high. The deal makes sense for Pfizer despite the high sticker price.
The Motley Fool June 22, 2011 Brian Orelli	Building on Pfizer's Blockbuster New data for an expanded indication for Lyrica.
The Motley Fool September 22, 2009 Brian Orelli	Nektar Tastes Sweet Nektar is getting an up-front payment of $125 million and AstraZeneca is taking over development of two of its compounds.
The Motley Fool April 29, 2008 Brian Orelli	Will These Drugs Get FDA Approval? Discovery Laboratories and Adolor are waiting FDA decisions on their drugs next month.
The Motley Fool December 16, 2003 David Nierengarten	Biotech's Next Phase It's been a great year for biotech, but don't count on a repeat in 2004. Here are some tips for evaluating biotechnology and pharmaceutical stocks.
The Motley Fool April 2, 2007 Brian Lawler	Progenics Submits for Its Future Progenics submits a New Drug Application for its lead compound. Whether the sales and royalty revenue that methylnaltrexone can bring in will be enough to support its current valuation is still in doubt.
The Motley Fool February 12, 2008 Brian Lawler	A Pre-Emptive Strike on the FDA Adolor will likely be waiting an extra three months for a decision on its lead drug Entereg.
The Motley Fool February 10, 2005 Karl Thiel	The Worst Has Happened. Time to Sell? Biotech stocks can be volatile, but dumping them in response to bad news isn't always the smartest option: Axonyx... Icos Pharmaceuticals... etc.
The Motley Fool March 31, 2008 Brian Orelli	Collateral Damage From an FDA Warning BioMimetic gets hit hard by a warning about a J&J drug.
The Motley Fool May 2, 2007 Brian Lawler	Progenics' Intriguing Study Results The development-stage drugmaker released clinical trial results for one of its compounds. Investors, take note.
Nursing February 2009 Daniel A. Hussar	New Drugs 09: Part 1 Learn about 10 new drugs, including nebivolol HCl, the newest beta-adrenergic blocking agent for hypertension.
The Motley Fool February 5, 2009 Brian Orelli	Glaxo Cuts Jobs, Guidance -- and the Kitchen Sink With sales dropping, more cuts were inevitable.
American Family Physician December 1, 2005 Christine Hsieh	Treatment of Constipation in Older Adults Effectiveness of a variety of treatments for chronic constipation in the elderly.
American Family Physician February 1, 2006	Chronic Constipation in Your Child An informative patient hand-out: What is constipation?... How common is chronic constipation... Why does my child have constipation?... etc.
American Family Physician October 15, 2006 Swegle & Logemann	Management of Common Opioid-Induced Adverse Effects Opioids are useful agents for managing acute and chronic pain. When prescribing these medications, an understanding of the risks and benefits is essential.
The Motley Fool September 16, 2008 Brian Lawler	Pfizer Puts Safety First Increased FDA scrutiny may motivate the pharmaceutical's new drug-safety site.